Microba Life Sciences Limited (ASX:MAP)

Market Cap	51.76M -58.0%
Revenue (ttm)	15.67M +29.6%
Net Income	-14.94M
EPS	-0.03
Shares Out	608.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90,453
Average Volume	283,962
Open	0.0860
Previous Close	0.0850
Day's Range	0.0860 - 0.0870
52-Week Range	0.0690 - 0.2450
Beta	2.41
RSI	47.95
Earnings Date	Jan 28, 2026

About Microba Life Sciences

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MAP

Financial Performance

In fiscal year 2025, Microba Life Sciences's revenue was 15.67 million, an increase of 29.60% compared to the previous year's 12.09 million. Losses were -14.94 million, -25.07% less than in 2024.